In part 2, Hans Lee, MD, shares practical tips for using linvoseltamab in heavily pretreated multiple myeloma and outlines trials that may expand its future role.
Hans Lee, MD
Advertisement
Hans Lee, MD, is the director of myeloma research at Sarah Cannon Research Institute.
Articles by Hans Lee, MD
The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and de-escalation to monthly maintenance.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
2
Value-Based Care Interventions and Management of CKD Progression
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
5
